How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?

It depends on the patient's case. In the setting of high-risk disease, whether clinically high risk or with HRC would prefer to use CAR-T in the second line. Currently, SoC allows for bispecific use beyond the 4th line, therefore would use triplet such as DPd (APOLLO) or IsaPD (ICARIA) second line f...

In the second line setting after front-line quadruplet therapy, we are typically talking about patients who are now triple-class exposed and refractory to lenalidomide, with some also being refractory to anti-CD38 therapy. Based on the data from MajesTEC-3, MajesTEC-9, and CARTITUDE-4, there is no q...

I monitor my patients very closely during follow-up after frontline quadruplet therapy. Patients will usually be relapsing off maintenance therapy with either lenalidomide or lenalidomide and daratumumab. For some patients, they may have completed their maintenance therapy and be on active surveilla...